A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the combination of erlotinib and pemetrexed versus
either pemetrexed alone and erlotinib alone, in terms of progression-free survival (time
until the objective worsening of the disease) in patients who have never smoked and have
locally advanced or metastatic Nonsquamous Non-Small Cell Lung Cancer who have failed a
first-line chemotherapy treatment.